Previous experiments using a cationic surfactant to detect hepatitis C virus (HCV) RNA in whole blood (WB) suggested that WB was a more plentiful source of viral RNA than was plasma. The relative HCV RNA titers in WB, plasma, peripheral blood mononuclear cells (PBMC), neutrophils, and red blood cells (RBC)/platelets from 10 patients with chronic HCV infection were compared. WB contained significantly more HCV RNA than plasma, which contained more HCV RNA than PBMC, neutrophils, or RBC/platelets (P õ .001). To determine if this increased sensitivity was clinically relevant, results of WB and plasma HCV RNA assays were compared with commercial quantitative and qualitative plasma HCV RNA assay results obtained for patients receiving interferon therapy. WB was significantly more sensitive than commercial plasma reverse transcriptionpolymerase chain reaction for detecting HCV RNA (P õ .005). These data indicate that a significant proportion of HCV RNA in peripheral blood is not identified by standard plasma RNA detection methods.
Hepatitis C virus (HCV) is a small enveloped RNA virus assays accurately determine the amount of virus in plasma or serum, HCV is also found in bone marrow and peripheral blood that is responsible for ú90% of cases of parenterally transmitted non-A, non-B hepatitis [1 -3] . Although acute infection mononuclear cells (PBMC) [12 -14] . These cellular reservoirs of HCV are not detected by plasma RNA detection methods. with HCV may be asymptomatic, the majority of patients develop persistent viremia and chronic hepatitis. About 15% -Nearly 40% of HCV-seropositive patients have measurable cryoglobulins, and a small percentage of patients develop the 20% of HCV-infected patients progress to end-stage liver disease and are considered for orthotopic liver transplantation.
mixed essential type II cryoglobulinemia syndrome [15, 16] .
Cryoprecipitates from these patients contain anti-HCV immuInterferon-a is the only recognized treatment for chronic HCV infection. Interferon therapy leads to normalization of serum noglobulins, rheumatoid factor, and HCV RNA. Cryoprecipitates appear to be enriched for HCV in comparison with plasma transaminase levels in Ç50% of patients, but unfortunately there is a high rate of relapse after discontinuation of therapy or serum [17, 18] , and these complexes may be cleared during the centrifugation step used to prepare plasma or serum from [4, 5] .
Clinical diagnosis of HCV infection relies on a positive EIA whole blood (WB). Consequently, routine serum or plasma measurements of HCV RNA may not provide an accurate deterresult and characteristic histologic findings on liver biopsy [3, 4, 6] . Increasingly, viral RNA in patient plasma or serum mination of the total HCV burden present in peripheral blood.
We recently described a method that uses a cationic surfacis monitored during treatment by use of qualitative reverse transcription -polymerase chain reaction (RT-PCR) and varitant (Catrimox-14) to extract HCV RNA from peripheral WB or isolated blood fractions such as plasma or blood cells [19] . ous quantitative methods, to guide the clinical management of chronic HCV infection [7 -11] . Although these quantitative When WB is mixed with Catrimox-14, RNA is rapidly precipitated as an insoluble complex containing the polyanionic nucleic acid on the interior, surrounded by a hydrophobic exterior [20] . This complex appears to protect the RNA from RNase body test (second-generation EIA and RIBAs; Abbott, Abbott identical for all samples and were as previously described [19] . All samples from each patient were processed together (RNA puriPark, IL), a positive plasma HCV RT-PCR assay (see below), cyclic serum elevation of hepatic transaminases (2 to 10 times fication and limiting dilution) to minimize the effects of solvent extraction as well as technician manipulation. Replicates of RNA normal), and characteristic histologic findings on liver biopsy. Patients were seen during routine clinic visits. Where indicated, pasamples showed a coefficient of variation of õ10% for mean log end point dilution titer. tients receiving therapy for chronic hepatitis secondary to HCV received 3 1 10 6 U of interferon-a2b subcutaneously three times RNA prepared from WB, plasma, or isolated blood cell fractions was studied. Serial dilutions of RNA were prepared in 1:2-, weekly. Samples obtained for routine clinical evaluation included qualitative and quantitative plasma HCV RNA determination (Am-1:50-, or 1:10-fold increments and assayed with nested PCR together with no-template (water) negative controls and known plicor; Roche Molecular Systems, Branchburg, NJ; performed commercially by OncQuest Speciality Laboratories, Santa Monica, HCV RNA-negative patient RNA controls to assess potential contamination. If any blank value or known control was positive, the CA). Samples were prepared and treated as recommended by OncQuest prior to and during shipment. experiment was repeated; however, this rarely occurred, since the recommendations of Kwok and Higuchi [27] were rigidly folPreparation of blood and blood cell fractions. WB was collected into acid-citrate-dextrose Vacutainer tubes (Becton Dickinlowed. The highest dilution of RNA producing detectable specific product was determined and was considered to be the dilution end son, Research Triangle Park, NC) and maintained at 2-4ЊC, and plasma or blood cell fractions were prepared within 2 h of collecpoint [24, 25] . tion. A complete blood count with white blood cell differential was obtained and used to determine the relative proportions of plasma or blood cells present in each aliquot of WB at the time
Results
of assay. Plasma was prepared (800 g for 10 min), and PBMC Limiting dilution experiments have previously been evaluwere prepared by ficoll-hypaque gradient centrifugation [19] . ated for their ability to assess relative concentrations of HCV PBMC were washed three times with ice-cold Hanks' balanced salt solution (HBSS) and, where indicated, PBMC were fraction-RNA in patient serum or isolated PBMC [28 -32] . This methated further on affinity columns (Biotex Laboratories, Edmonton, odology has been shown to be comparable to commercial Canada) to prepare enriched fractions of CD4 or CD8 cells by use assays when the RNA concentration tested is within the range of the protocol supplied by the manufacturer [21] . Purity of the that generates a linear concentration of PCR amplification prod-CD4 and CD8 cells was assessed with flow cytometry (University ucts [28] . To ensure that the concentration of RNA tested in of Iowa Flow Cytometry Facility). Enrichment of ú90% (CD4 our RT-PCR assays could be accurately compared, we analyzed cells) and 62% (CD8 cells) was obtained. Monocytes were pre-WB RNA obtained from various volumes of blood from 2 pared by overnight attachment of PBMC to tissue culture plates different HCV RNA -positive patients. The WB HCV RNA [22] . Highly purified neutrophils (ú95%) [23] were prepared by end point dilution titers (which represent the inverse of the ficoll/hypaque centrifugation, dextrose sedimentation, and hypoabsolute viral RNA titer) were linear with respect to the volume tonic lysis of RBC. Purified neutrophils were washed three times of WB used to prepare the RNA from each donor (r Å .985, with ice-cold excess HBSS before RNA preparation. RBC/platelet fractions were recovered from the ficoll-hypaque pellets after sepa- figure 1A ). Furthermore, the yield of RNA from WB prepared ration of leukocytes. Cells were counted, and aliquots of washed, by the Catrimox procedure was linear throughout the assay purified neutrophil or RBC/platelet fractions were added directly range (r Å .987, figure 1B ). Consequently, our method provided to 1.0 mL of Catrimox in amounts adjusted to equal the number an accurate relative measure of input RNA, based on the volof cells found in 200 mL of WB. Control experiments verified that ume of blood used to prepare RNA in this study.
aliquots of the third wash buffer were free of HCV RNA sequences.
To estimate the sensitivity of our WB assay, we determined RNA preparation and RT-PCR. RNA was purified from WB, the HCV RNA limiting dilution end point in 2 independent plasma, or blood cellular fractions following precipitation with
samples of WB RNA and tested the concentration of the same Catrimox-14 as previously described [19] . Isolated plasma or puri-RNA preparation with a commercial test (Amplicor). The limit fied fractions of blood cells were added directly to 1.0 mL of of detection for the WB and plasma RT-PCR method was
Catrimox in amounts adjusted to equal the respective amount found Ç240 genome equivalents/mL of WB or plasma (data not in 200 mL of WB. Where indicated, the quantity of isolated total blood RNA was determined by measurement of absorbance at 260 shown), which correlates with the limit of detection of the nm after resuspension of RNA in molecular biology-grade 5 M qualitative commercial test (200 copies/mL). The fact that WB urea.
RNA was able to generate HCV PCR products when the comPrimers (purchased from the University of Iowa College of mercial assay was used provided additional assurance of the Medicine DNA Core Facility) were prepared from known sequality of template RNA prepared by the Catrimox procedure quences of the highly conserved 5-nontranslated region of HCV, on WB.
and nested RT-PCR was performed as described previously [19] .
To determine the relative concentration of HCV RNA in Specific DNA products (250 bp) were analyzed on 1.6% agarose WB, plasma, PBMC, neutrophils, and RBC/platelets, limiting gels after staining with ethidium bromide. To control for known dilution experiments were used on RNA samples prepared from variations in PCR efficiency [24] [25] [26] , rigorous standardization of blood obtained from 10 patients with chronic HCV infection. for patient A and 10 5 for patient B. In contrast, the equivalent the most variability of HCV RNA detection, with 5 of 8 patients tested having no detectable HCV RNA. volume of plasma showed titers of 10 3 in both patients, and lower titers were observed for PBMC, neutrophil, and RBC/ Although the data in figure 3 depict relative HCV RNA titers in the respective purified fractions, some HCV RNA could platelet preparations. HCV sequences were not seen in the neutrophil preparation from patient B.
have been lost during purification and washing of the WB cellular fractions. To determine if this was the case, we assessed Cumulative data for all 10 patients are shown in figure 3 . The titer of HCV RNA varied among individual WB samples the HCV RNA titers in WB, plasma, and the crude cellular pellet remaining after plasma preparation from 2 patients. The (10 4 to 10 8 , P õ .001), and the HCV RNA titer in WB ranged from 10-to 1000-fold higher than that in any of the correspond-HCV RNA titers of plasma plus crude pellets were about equal to that of WB (data not shown). After two washes of the pellet ing blood fractions (P õ .001). Individual sample equivalents of plasma, PBMC, neutrophil, and RBC/platelet fractions exwith balanced salt solution, 10% -50% of the original titer of viral RNA was still associated with the pellet, and subsequent hibited titers of 0 to 10 4 , 0 to 10 5 , 0 to 10 4 , and 0 to 10 1 , respectively. The data in figure 3 were analyzed with a comwashes failed to remove additional HCV RNA from the cell pellet. These experiments suggest that the excess HCV RNA pletely randomized design (with unequal group sizes) for analysis of variance with Fisher's least significant difference test to found in WB relative to plasma is either intracellular virus or virus adherent to cells and pelleted during plasma preparation determine the significance between grouped fractions. Data analyzed as paired comparisons within patient groups by use (or both). Large complexes of virus and specific antibody may also remain insoluble and separate with the cellular pellet. of a t distribution showed the same level of significance. WB contained significantly more HCV RNA than plasma (P PBMC consist of monocytes, B lymphocytes, and a variety of T lymphocytes, including CD4 and CD8 cells. We evaluated õ .001), and plasma contained significantly more HCV RNA than PBMC (P õ .005), which contained more HCV RNA monocyte, CD4 cell -enriched, and CD8 cell -enriched fractions from 2 patients for the presence of HCV RNA. HCV than neutrophils (P õ .001). Neutrophil fractions demonstrated / 9d2b$$jy31 05-01-97 08:21:08 jinfal UC: J Infect this possibility, a constant amount of HCV RNA -positive plasma was added to various amounts of HCV RNA -negative WB or HCV RNA -negative plasma. After RNA extraction, the relative titers of HCV RNA were determined. Table 1 demonstrates that the same titer of HCV RNA was detected regardless of the volume of HCV RNA -negative WB or plasma added to the HCV RNA -positive plasma. This titer was the same as that determined in the HCV RNA -positive plasma without HCV RNA -negative WB or plasma added. This demonstrates that WB does not enhance recovery of HCV RNA present in plasma. Similarly, no decrease in titer was found when HCV RNA -positive plasma was added to HCV RNA -negative plasma, excluding an inhibitory effect of plasma on RNA extraction or subsequent RT-PCR.
To compare the sensitivity of Catrimox WB and plasma HCV RNA assays with commercial quantitative and qualitative HCV RNA detection systems, we selected patients with chronic hepatitis C who were receiving standard dosages of interferon therapy (3 1 10 6 U subcutaneously three times weekly for 6 months). All patients were HCV RNA -positive before interferon treatment. Blood and plasma samples were obtained for Catrimox RNA extraction during the same blood sampling for which the commercial HCV RNA assay was obtained. Patients with a positive commercial quantitative HCV RNA test, patients with negative (nondetectable) quantitative HCV RNA, and patients with a prior negative quantitative test who were further assessed with the commercial qualitative HCV RNA assay were studied (table 2). All Catrimox WB and plasma samples were positive if the commercial quantitative test was positive (group I, table 2); however, 11 (69%) of 16 patients Finally, for 19 patients who had a negative commercial quantitative HCV RNA result, a commercial qualitative HCV RNA result was obtained. Of these 19 patients, 13 (68%) were posi-RNA titers of at least 10 2 were determined for each of these cell fractions, suggesting that HCV is present in multiple comtive by Catrimox WB HCV RT-PCR but only 2 (11%) were positive by the commercial assay (group 3, table 2; P õ .005, ponents of PBMC (data not shown). Since these WB samples contained an HCV RNA titer of 10 5 , the lymphocyte HCV WB vs. qualitative commercial RT-PCR). Catrimox plasma HCV RT-PCR also detected HCV-positive patients (21%) not RNA does not constitute a major fraction of the total circulating HCV in WB. Since pure CD4 and CD8 lymphocyte populations revealed by the quantitative assay in this group; however, the Catrimox plasma assay was not statistically different from the could not be obtained, the relative quantity of HCV RNA present between these cell types could not be determined.
commercial qualitative assay. Group II and III patients (table  2) were receiving interferon therapy at the time of testing and An alternate explanation for the observed increased titer of HCV RNA in WB relative to plasma is that HCV RNA recovthus had reduced concentrations of HCV RNA in plasma compared with their pretreatment studies. ery may be enhanced during RNA extraction. This enhancement could be due to a ''carrier'' effect, in which total cellular Discussion RNA coextracted with the plasma HCV RNA increases the recovery of viral RNA. In addition, the excess cellular RNA HCV is known to circulate in peripheral blood in a variety of forms. Virus that is presumably antibody-free (and highly may provide increased resistance to endonucleases. To examine / 9d2b$$jy31 05-01-97 08:21:08 jinfal UC: J Infect . WB contained significantly more HCV RNA than plasma (P õ .001), and plasma contained significantly more HCV RNA than PBMC (P õ .005), which contained more HCV RNA than neutrophils (P õ .001). F, none detected.
infectious) and HCV-immunoglobulin immune complexes these isolated blood fractions may be important in understanding the natural history, response to treatment, and pathogenesis have been recovered in serum and plasma [33, 34] . Viral RNA of HCV chronic infection. has also been identified in PBMC [12 -14] , bound in large Our findings provide a relative quantification of HCV RNA complexes of host antibody and rheumatoid factor in the form in plasma and the cellular compartments of peripheral WB. of cryoprecipitates [15 -18] , and may also exist engulfed in
The relative titer of HCV RNA was highest in unfractionated phagocytes. Studies evaluating the relative distribution of HCV WB, with plasma containing the highest concentration of HCV RNA within the various compartments of blood have not been RNA among the individual blood compartments. Analysis of reported, although identification of HCV RNA sequences in the different blood cell types demonstrated that PBMC have significantly higher RNA titers than do neutrophil or RBC/ platelet fractions and that among the cell types of PBMC, contained an insignificant titer of HCV RNA compared with the HCV RNA titer present in WB. As might be expected, the transferase levels should include WB HCV RNA detection. These studies are currently underway in our laboratory. In addition, we are evaluating the prognostic benefit of measuring particular cell is permissive for HCV replication. Alternatively, virus or virus-protein complexes could adhere to specific recep-WB HCV RNA levels in patients receiving interferon therapy. tors on the cell surface and be pelleted during preparation of plasma. For example, virus-immunoglobulin complexes could replication of the virus. Replicative intermediates have been demonstrated in PBMC in some studies [12, 13, 36, 37] but not in others [38] , and successful in vitro infection and extended
